Invasive Mycoses: Strategies for Effective Management
Section snippets
General Approaches to the Management of Invasive Fungal Infections
Four general approaches are available for the management of IFIs: prophylaxis and empiric, preemptive, or targeted therapy.12, 13 A prophylactic approach may be warranted when a patient is at sufficient risk of IFI and its negative consequences to justify the cost and potential exposure of an uninfected individual to drug-related toxicity. In addition to increased costs and possible exposure to drug-related toxicities, prophylaxis also provides an environment for development of drug-resistant
Factors Influencing Selection of Antifungal Agent
Antifungal agents available for the management of IFIs include polyenes (amphotericin B deoxycholate and 3 lipid formulations of amphotericin B), triazoles (fluconazole, itraconazole, voriconazole, and posaconazole), echinocandins (caspofungin, micafungin, and anidulafungin), and flucytosine.31, 32 These agents differ in spectrum of activity, PK/PD properties, indications, safety, cost, and ease of use or convenience. All of these factors are important to consider when selecting an antifungal
Therapeutic Drug Monitoring
In a recent review, Lewis11 listed 3 general criteria useful for identifying pharmaceutical agents as suitable candidates for therapeutic drug monitoring: (1) unpredictable population PKs or an unpredictable dose-response relationship, (2) a narrow therapeutic window, and (3) a clinically defined therapeutic range. Of the currently available antifungal agents, only the lipophilic triazoles (itraconazole, voriconazole, and posaconazole) and flucytosine meet all 3 criteria well enough to be
Case 1
A 44-year-old man with myelodysplastic syndrome treated >90 days ago with a matched unrelated-donor, allogeneic HSCT, and a history of extensive graft-versus-host disease (GVHD) presented with new pleural-based nodular lesions, pleurisy, and GVHD of the skin. He was admitted to the hospital. A medical history revealed the patient had been receiving a prophylactic anti-infective regimen consisting of liposomal amphotericin B (3 times a week), valganciclovir, sulfamethoxazole-trimethoprim, and
Case 2
A 58-year-old woman with leukemia and presumed aspergillosis presented with progressing pneumonia despite what seemed to be appropriate antifungal therapy (voriconazole, 6 mg/kg IV every 12 hours for the first day, followed by 4 mg/kg IV every 12 hours thereafter).29
This is a patient type commonly seen in tertiary care hematology centers—i.e., a patient with documented or presumed pulmonary aspergillosis who exhibits infectious disease progression despite recommended first-line therapy. The
Mucormycosis
Mucormycosis is an important and increasing (although still relatively uncommon) cause of morbidity and mortality in immunocompromised patients. In the current environment, clinicians should consider possible mucormycosis in patients with signs and symptoms of infection, particularly in those with progressing disease despite antifungal treatment covering most other fungal pathogens.
Summary
When presented with a patient with or at risk for IFI, clinicians must weigh various factors when individualizing therapy to optimize outcomes. Antifungal drug options have increased over recent years, and the various agents differ in terms of spectrum of activity, PK/PDs, indications, safety, cost, and ease of use. These differences should be considered and an attempt made to match these drug-related characteristics with host-related factors to provide the best chance for IFI eradication with
Author Disclosures
The author of this article has disclosed the following industry relationships:
Dimitrios P. Kontoyiannis, MD, ScD, has received consulting fees and/or fees for non-CME services from Astellas, Enzon, Merck & Co., Inc., Pfizer and funds for contracted research from Astellas, Enzon, Merck & Co., Inc.
Acknowledgments
I thank Russell E. Lewis, PharmD, for useful comments. Editorial support for this publication was provided by Global Education Exchange, Inc., Freehold, New Jersey.
References (154)
Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment
Am J Med
(2012)Invasive mycoses: diagnostic challenges
Am J Med
(2012)- et al.
Nosocomial candidemia at a general hospital: prognostic factors and impact of early empiric treatment on outcome (2002–2005)
Med Clin (Barc)
(2010) - et al.
Therapy for fungal diseases: opportunities and priorities
Trends Microbiol
(2010) - et al.
Agents for treatment of invasive fungal infections
Otolaryngol Clin North Am
(2000) - et al.
Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants
Blood
(2004) - et al.
Chronic phototoxicity and aggressive squamous cell carcinoma of the skin in children and adults during treatment with voriconazole
J Am Acad Dermatol
(2010) - et al.
Multiple aggressive squamous cell carcinomas associated with prolonged voriconazole therapy in four immunocompromised patients
Clin Microbiol Infect
(2010) - et al.
Voriconazole exposure and geographic location are independent risk factors for squamous cell carcinoma of the skin among lung transplant recipients
J Heart Lung Transplant
(2010) - et al.
Hepatic safety of voriconazole after allogeneic hematopoietic stem cell transplantation
Biol Blood Marrow Transplant
(2010)
Effects of liposomal amphotericin B versus an amphotericin B lipid complex on liver histopathology in patients with hematologic malignancies and invasive fungal infections: a retrospective, nonrandomized autopsy study
Clin Ther
Clinical pharmacology of antifungal compounds
Infect Dis Clin North Am
Epidemiology of invasive mycoses in North America
Crit Rev Microbiol
Diagnostic challenges and recent advances in the early management of invasive fungal infections
Eur J Haematol
Detection and investigation of invasive mould disease
J Antimicrob Chemother
Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis
Clin Infect Dis
Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study
Clin Infect Dis
Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality
Antimicrob Agents Chemother
Pulmonary aspergillosis: early diagnosis improves survival
Respiration
Antifungal therapeutic drug monitoring: established and emerging indications
Antimicrob Agents Chemother
Antifungal drug monitoring
Curr Fungal Infect Rep
Antifungal treatment strategies in patients with haematological diseases or cancer: from prophylaxis to empirical, pre-emptive and targeted therapy
Mycoses
Patients at high risk of invasive fungal infections: when and how to treat
Drugs
Candidemia in non-neutropenic critically ill patients: analysis of prognostic factors and assessment of systemic antifungal therapy
Intensive Care Med
The effect of time to antifungal therapy on mortality in candidemia associated septic shock
Am J Ther
Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial
Clin Infect Dis
Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study
Clin Infect Dis
Antifungal prophylaxis and treatment in patients with hematological malignancies
Expert Rev Anti Infect Ther
Antifungal prophylaxis in hematopoietic stem cell transplant recipients: the unfinished tale of imperfect success
Bone Marrow Transplant
Fungal infections in leukemia patients: how do we prevent and treat them?
Clin Infect Dis
Treatment and timing in invasive mould disease
J Antimicrob Chemother
Approaches to the management of invasive fungal infections in hematologic malignancy and hematopoietic cell transplantation
J Clin Oncol
Clinical practice guidelines for the management of blastomycosis: 2008 update by the Infectious Diseases Society of America
Clin Infect Dis
Coccidioidomycosis
Clin Infect Dis
Clinical practice guidelines for the management of sporotrichosis: 2007 update by the Infectious Diseases Society of America
Clin Infect Dis
Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America
Clin Infect Dis
Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America
Clin Infect Dis
Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America
Clin Infect Dis
Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America
Clin Infect Dis
Pharmacology of systemic antifungal agents
Clin Infect Dis
Final results of APRICOT: A randomized, partially blinded, international trial evaluating peginterferon-a-2a + ribavirin vs. interferon-a-2a + ribavirin in the treatment of HCV in HIV/HCV co-infection
Adverse effects of antifungal therapies in invasive fungal infections: review and meta-analysis
Eur J Clin Microbiol Infect Dis
Renal impairment and amphotericin B formulations in patients with invasive fungal infections
Med Mycol
Vrend
Echinocandin antifungal drugs in fungal infections: a comparison
Drugs
Hepatotoxicity of antifungal agents
Curr Opin Investig Drugs
Drug-drug interactions of antifungal agents and implications for patient care
Expert Opin Pharmacother
Erythropoietin concentration in amphotericin B-induced anemia
Antimicrob Agents Chemother
Adverse effects of voriconazole: analysis of the French Pharmacovigilance Database
Ann Pharmacother
Central nervous system toxicity associated with liposomal amphotericin B therapy for cutaneous leishmaniasis
Am J Trop Med Hyg
Cited by (0)
Statement of author disclosure: Please see the Author Disclosures section at the end of this article.
This supplement is in part based on a closed roundtable meeting that was held June 7, 2011 in New York City and was jointly sponsored by Postgraduate Institute for Medicine and Global Education Exchange through an educational grant from Merck & Co., Inc. The webinar was peer-reviewed and accepted as a free multimedia activity of The American Journal of Medicine and is available at www.antifungaltherapy2.net.